Nebenwirkungen · Isentress
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.8 · PDF-Seite 63
HOS-119281 · Präparat HOS-094905
HIV-1 Exposed Neonates In IMPAACT P1110 (see section 5.2) eligible infants were at least 37 weeks gestation and at least 2 kg in weight. Sixteen (16) neonates received 2 doses of ISENTRESS in first 2 weeks of life, and 26 neonates received 6 weeks of daily dosing; all were followed for 24 weeks. There were no drug related clinical adverse experiences and three drug-related laboratory adverse experiences (one a transient Grade 4 neutropenia in a subject receiving zidovudine containing prevention of mother to child transmission (PMTCT), and two bilirubin elevations (one each, Grade 1 and Grade 2) considered non-serious and not requiring specific therapy).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 3fceaa301ede43b37ee7e71182ad16ff0d5f9989b1068072efdcc4a3bea664b9 · Zeichen 15974–16635 im Abschnitt